564 related articles for article (PubMed ID: 30772256)
21. Relationship between non-alcoholic steatohepatitis, PNPLA3 I148M genotype and bone mineral density in adolescents.
Mosca A; Fintini D; Scorletti E; Cappa M; Paone L; Zicari AM; Nobili V; Byrne CD
Liver Int; 2018 Dec; 38(12):2301-2308. PubMed ID: 30176114
[TBL] [Abstract][Full Text] [Related]
22. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis.
Smagris E; BasuRay S; Li J; Huang Y; Lai KM; Gromada J; Cohen JC; Hobbs HH
Hepatology; 2015 Jan; 61(1):108-18. PubMed ID: 24917523
[TBL] [Abstract][Full Text] [Related]
23. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro.
Pirazzi C; Adiels M; Burza MA; Mancina RM; Levin M; Ståhlman M; Taskinen MR; Orho-Melander M; Perman J; Pujia A; Andersson L; Maglio C; Montalcini T; Wiklund O; Borén J; Romeo S
J Hepatol; 2012 Dec; 57(6):1276-82. PubMed ID: 22878467
[TBL] [Abstract][Full Text] [Related]
24. Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease.
Jiang ZG; Tapper EB; Kim M; Connelly MA; Krawczyk SA; Yee EU; Herman MA; Mukamal KJ; Lai M
J Clin Gastroenterol; 2018; 52(5):444-451. PubMed ID: 28362682
[TBL] [Abstract][Full Text] [Related]
25. IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease.
Park J; Zhao Y; Zhang F; Zhang S; Kwong AC; Zhang Y; Hoffmann HH; Bushweller L; Wu X; Ashbrook AW; Stefanovic B; Chen S; Branch AD; Mason CE; Jung JU; Rice CM; Wu X
J Hepatol; 2023 Jan; 78(1):45-56. PubMed ID: 36049612
[TBL] [Abstract][Full Text] [Related]
26. The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls.
Valenti L; Rametta R; Ruscica M; Dongiovanni P; Steffani L; Motta BM; Canavesi E; Fracanzani AL; Mozzi E; Roviaro G; Magni P; Fargion S
BMC Gastroenterol; 2012 Aug; 12():111. PubMed ID: 22898488
[TBL] [Abstract][Full Text] [Related]
27. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease.
Valenti L; Alisi A; Galmozzi E; Bartuli A; Del Menico B; Alterio A; Dongiovanni P; Fargion S; Nobili V
Hepatology; 2010 Oct; 52(4):1274-80. PubMed ID: 20648474
[TBL] [Abstract][Full Text] [Related]
28. PNPLA3 I148M and response to treatment for hepatic steatosis: A systematic review.
Boeckmans J; Gatzios A; Schattenberg JM; Koek GH; Rodrigues RM; Vanhaecke T
Liver Int; 2023 May; 43(5):975-988. PubMed ID: 36719059
[TBL] [Abstract][Full Text] [Related]
29. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.
Scorletti E; West AL; Bhatia L; Hoile SP; McCormick KG; Burdge GC; Lillycrop KA; Clough GF; Calder PC; Byrne CD
J Hepatol; 2015 Dec; 63(6):1476-83. PubMed ID: 26272871
[TBL] [Abstract][Full Text] [Related]
30. Four-Week Omega-3 Supplementation in Carriers of the Prosteatotic PNPLA3 p.I148M Genetic Variant: An Open-Label Study.
Kuttner CS; Mancina R; Wagenpfeil G; Lammert F; Stokes CS
Lifestyle Genom; 2019; 12(1-6):10-17. PubMed ID: 31454802
[TBL] [Abstract][Full Text] [Related]
31. Association of PNPLA3 rs738409 G/C gene polymorphism with nonalcoholic fatty liver disease in children: a meta-analysis.
Tang S; Zhang J; Mei TT; Guo HQ; Wei XH; Zhang WY; Liu YL; Liang S; Fan ZP; Ma LX; Lin W; Liu YR; Qiu LX; Yu HB
BMC Med Genet; 2020 Aug; 21(1):163. PubMed ID: 32811452
[TBL] [Abstract][Full Text] [Related]
32. Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans.
Liu W; Anstee QM; Wang X; Gawrieh S; Gamazon ER; Athinarayanan S; Liu YL; Darlay R; Cordell HJ; Daly AK; Day CP; Chalasani N
Aging (Albany NY); 2016 Oct; 9(1):26-40. PubMed ID: 27744419
[TBL] [Abstract][Full Text] [Related]
33. Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis.
Carlsson B; Lindén D; Brolén G; Liljeblad M; Bjursell M; Romeo S; Loomba R
Aliment Pharmacol Ther; 2020 Jun; 51(12):1305-1320. PubMed ID: 32383295
[TBL] [Abstract][Full Text] [Related]
34. The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients.
Vespasiani-Gentilucci U; Gallo P; Porcari A; Carotti S; Galati G; Piccioni L; De Vincentis A; Dell'Unto C; Vorini F; Morini S; Riva E; Picardi A
Scand J Gastroenterol; 2016 Aug; 51(8):967-73. PubMed ID: 27150500
[TBL] [Abstract][Full Text] [Related]
35. PNPLA3 I148M Polymorphism in Patients with Nonalcoholic Fatty Liver Disease, Obesity and Prediabetes.
Karamfilova V; Gateva A; Assyov Y; Alexiev A; Savov A; Yaneva N; Ivanova I; Ivanova-Boyanova R; Ivanova R; Vlahova Z; Mateva L; Kamenov Z
J Gastrointestin Liver Dis; 2019 Dec; 28(4):433-438. PubMed ID: 31826069
[TBL] [Abstract][Full Text] [Related]
36. PNPLA3 I148M polymorphism and progressive liver disease.
Dongiovanni P; Donati B; Fares R; Lombardi R; Mancina RM; Romeo S; Valenti L
World J Gastroenterol; 2013 Nov; 19(41):6969-78. PubMed ID: 24222941
[TBL] [Abstract][Full Text] [Related]
37. The Role of
Liu M; Park S
Nutrients; 2024 Apr; 16(8):. PubMed ID: 38674929
[TBL] [Abstract][Full Text] [Related]
38. Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome.
Stättermayer AF; Traussnigg S; Aigner E; Kienbacher C; Huber-Schönauer U; Steindl-Munda P; Stadlmayr A; Wrba F; Trauner M; Datz C; Ferenci P
J Trace Elem Med Biol; 2017 Jan; 39():100-107. PubMed ID: 27908400
[TBL] [Abstract][Full Text] [Related]
39. Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C.
De Nicola S; Dongiovanni P; Aghemo A; Cheroni C; D'Ambrosio R; Pedrazzini M; Marabita F; Donnici L; Maggioni M; Fargion S; Colombo M; De Francesco R; Valenti L
PLoS One; 2014; 9(8):e106022. PubMed ID: 25171251
[TBL] [Abstract][Full Text] [Related]
40. The PNPLA3 I148M variant promotes lipid-induced hepatocyte secretion of CXC chemokines establishing a tumorigenic milieu.
Nischalke HD; Lutz P; Bartok E; Krämer B; Langhans B; Frizler R; Berg T; Hampe J; Buch S; Datz C; Stickel F; Hartmann G; Strassburg CP; Nattermann J; Spengler U
J Mol Med (Berl); 2019 Nov; 97(11):1589-1600. PubMed ID: 31637480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
